ARTICLE | Company News
FDA extends review for exenatide once weekly
February 26, 2010 2:05 AM UTC
FDA extended the PDUFA date to March 12 from March 5 for an NDA from Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) for exenatide once weekly to treat Type II diabetes. The extension is a result of federal...